Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Puma Biotechnology (PBYI)
NASDAQ:PBYI
Holding PBYI?
Track your performance easily
PBYI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.13 - $7.73
Previous Close$2.54
Volume459.24K
Average Volume (3M)468.16K
Market Cap
$124.58M
Enterprise Value$126.33M
Total Cash (Recent Filing)$96.83M
Total Debt (Recent Filing)$98.59M
Price to Earnings (P/E)13.9
Beta1.06
Next Earnings
Oct 31, 2024EPS Estimate
$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.18
Shares Outstanding49,046,723
10 Day Avg. Volume465,046
30 Day Avg. Volume468,156
Standard Deviation0.24
R-Squared0.05
Alpha-0.00512
Financial Highlights & Ratios
Price to Book (P/B)-15.97
Price to Sales (P/S)0.55
Price to Cash Flow (P/CF)29.10
P/FCF Ratio29.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.58
Enterprise Value/Gross Profit0.73
Enterprise Value/Ebitda6.49
Forecast
1Y Price Target
$4.33Price Target Upside70.47% Upside
Rating ConsensusHold
Number of Analyst Covering3
Puma Biotechnology News
PremiumCompany Announcements
Puma Biotechnology Stockholders Elect Leadership and Approve Amendments
Bulls Say, Bears Say
Bulls Say
EarningsPuma reported 2Q24 revenue and non-GAAP EPS of $47.1M and ($0.05), respectively, compared to estimates of $41.4M and ($0.14), respectively.
Legal/PatentPatent infringement win could reap financial benefits for Puma as the jury verdict found the patents to be infringed by AstraZeneca and not invalid, awarding the plaintiffs $107.5M in damages.
Product PerformanceNCCN guidelines include Nerlynx combinations as category 2B potential targeted therapies for patients with ER+/HER2- or ER-/HER2-metastatic (stage IV) breast cancer.
Bears Say
Enrollment2Q24 performance was negatively impacted by the decline in enrollment that was previously discussed.
Financial PerformancePuma reported a GAAP net loss of $4.5MM or ($0.09) on a per share basis.
SalesPuma sold 2,515 bottles of Nerlynx that included a $2.3MM inventory drawdown from distributors.
---
Ownership Overview
37.11% Insiders
10.77% Mutual Funds
29.61% Other Institutional Investors
22.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PBYI FAQ
What was Puma Biotechnology’s price range in the past 12 months?
Puma Biotechnology lowest stock price was $2.13 and its highest was $7.73 in the past 12 months.
What is Puma Biotechnology’s market cap?
Currently, no data Available
When is Puma Biotechnology’s upcoming earnings report date?
Puma Biotechnology’s upcoming earnings report date is Oct 31, 2024 which is in 67 days.
How were Puma Biotechnology’s earnings last quarter?
Puma Biotechnology released its earnings results on Aug 01, 2024. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.13 by $0.04.
Is Puma Biotechnology overvalued?
According to Wall Street analysts Puma Biotechnology’s price is currently Undervalued.
Does Puma Biotechnology pay dividends?
Puma Biotechnology does not currently pay dividends.
What is Puma Biotechnology’s EPS estimate?
Puma Biotechnology’s EPS estimate is $0.33.
How many shares outstanding does Puma Biotechnology have?
Puma Biotechnology has 49,046,722 shares outstanding.
What happened to Puma Biotechnology’s price movement after its last earnings report?
Puma Biotechnology reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.13. Following the earnings report the stock price went up 9.429%.
Which hedge fund is a major shareholder of Puma Biotechnology?
Among the largest hedge funds holding Puma Biotechnology’s share is Royce & Associates LLC. It holds Puma Biotechnology’s shares valued at 38K.
---
Puma Biotechnology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.33 (70.47% Upside)
$4.33 (70.47% Upside)
Blogger Sentiment
Bullish
PBYI Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 62.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $81.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.53%
12-Months-Change
Fundamentals
Return on Equity
22.10%
Trailing 12-Months
Asset Growth
2.25%
Trailing 12-Months
Company Description
Puma Biotechnology
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
---
PBYI Company Deck
---
PBYI Earnings Call
Q2 2024
0:00 / 0:00
---
PBYI Stock 12 Month Forecast
Average Price Target
$4.33
▲(70.47% Upside)
Technical Analysis
Best Analysts Covering PBYI
1 Year
1 Year Success Rate
14/27 ratings generated profit
1 Year Average Return
-1.69%
reiterated a buy rating 23 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 51.85% of your transactions generating a profit, with an average return of -1.69% per trade.
---